Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917315 | 0.90 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL2513545 | 0.90 | TLR7 (0.40) | TLR7TLR8 | |
| SCHEMBL9979161 | 0.89 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL2513263 | 0.89 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL9979143 | 0.88 | TLR7 (0.38) | TLR7TLR8 | |
| SCHEMBL9979057 | 0.87 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL9979428 | 0.86 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL9979077 | 0.86 | MTNR1A (0.40) | TLR7TLR8 | |
| SCHEMBL9978979 | 0.85 | TLR7 (0.36) | TLR7TLR8 | |
| SCHEMBL19917075 | 0.85 | TLR7 (0.37) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | claimed |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMANY | 2011-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IFNAR1 | TLR7 171/4885TLR8 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.